Braftovi FDA Approval History
Last updated by Judith Stewart, BPharm on Oct 13, 2023.
FDA Approved: Yes (First approved June 27, 2018)
Brand name: Braftovi
Generic name: encorafenib
Dosage form: Capsules
Company: Pfizer Inc.
Treatment for: Melanoma, Metastatic, Colorectal Cancer, Non-Small Cell Lung Cancer
Braftovi (encorafenib) is a kinase inhibitor used for the treatment of melanoma, colorectal cancer, and non-small cell lung cancer.
- Braftovi is indicated:
- in combination with binimetinib, for the treatment of patients with unresectable or metastatic melanoma with a BRAF V600E or V600K mutation, as detected by an FDA-approved test.
- in combination with cetuximab, for the treatment of adult patients with metastatic colorectal cancer (CRC) with a BRAF V600E mutation, as detected by an FDA-approved test, after prior therapy.
- in combination with binimetinib, for the treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) with a BRAF V600E mutation, as detected by an FDA-approved test.
Development timeline for Braftovi
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
